Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chrysanthemum refers to a genus of flowering plants in the Asteraceae family, native to Asia and northeastern Europe. The flowers and aerial parts are widely used in traditional Chinese medicine (TCM) and as herbal tea. Chrysanthemum contains flavonoids and phenolic compounds with antioxidant and anti-inflammatory properties. It is traditionally used for conditions such as hypertension, angina, fever, common cold, diabetes, stroke, inflammation-related diseases, osteoarthritis symptoms relief, liver detoxification support, gut health improvement (including indigestion), immune system boosting due to antibacterial/antiviral effects, and as a natural insecticide for lice treatment. Preclinical studies suggest cytotoxicity against cancer cells (in vitro), neuroprotective effects in ischemic stroke patients (small studies), antihyperlipidemic activity, anti-atherosclerotic effects and potential reversal of multidrug resistance in cancer cell lines. However clinical evidence supporting these uses is limited or lacking[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chrysanthemum.